Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals' Lead Antibody
... and in combination with approved chemotherapeutic agents
versus chemotherapy alone on the frequency of ... or in combination with standard chemotherapeutic agents
significantly decreases the ratio of cancer stem ... that treatment with certain chemotherapeutic agents
alone may actually serve to amplify the risk for ...
Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
... said Jeffrey Glenn. "These virus specific agents
in development at Eiger possess the promise of ... on the discovery and development of new antiviral agents
against novel targets for the treatment of ... includes repurposed clinical stage therapeutic agents
as well as preclinical NCEs from discovery that ...
Cardinal Health Completes Biotech Acquisition
... Administration (FDA) to manufacture PET imaging agents
that are used by physicians to diagnose various ... to support clinical trials of new and novel PET agents
to advance the future of molecular imaging. In ... helping manufacturers expand the pipeline of new agents
that will aid in the diagnosis and treatment of ...
VisEn Launches New Cat-K FAST(TM) Fluorescence Molecular Imaging Agent
... Technology") in vivo agent platform. FAST agents
are based on high-performance, activatable ... .
VisEn's proprietary fluorescence imaging agents
and labels are designed to provide the industry's ... offers over 25 different fluorescence molecular agents
for imaging key disease-associated biologic ...
Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients
... hydrochloride or any combination of these agents
were eligible for enrollment and immediately ... hydrochloride or any combination of these agents
were eligible for enrollment and immediately ... usually require treatment with phosphate-binding agents
to lower and maintain serum phosphorus at ...
Raptiva Withdrawal Offers Upside for Enbrel and Humira According to Latest BioTrends Survey of U.S. Dermatologists
... leaders for topical agents.
Use of oral agents
to treat moderate and severe psoriasis declined for the second year in a row. Use of oral agents
is divided primarily between methotrexate and ... biologics in the future," increased use of these agents
and rapid adoption of newly approved brands may ...
VisEn Launches Next-Generation Fast ('Fluorescence Activatible Sensor Technology') Agent Platform for Expanded Performance in Imaging Disease Biomarkers In Vivo
... Newly developed by VisEn Medical, FAST imaging agents
are smaller molecule, biocompatible, activatible fluorescent agents
that combine increased biomarker specificity with ... new MMPSense 750 FAST , the first of the FAST agents
to be launched by VisEn, was described today in a ...
New Weapon in BioDefense Research: NanoLogix Kit Speeds Rapid Diagnostics of Anthrax and Bubonic Plague
... a preferred bio-weapon of terrorists. As these agents
are highly dangerous all testing was done in a ... rapid confirmation of the presence of biological agents
can mean the difference between life and death, ... in determining the threat posed by biologic agents
will contribute to a more rapid diagnosis and ...
CeNeRx BioPharma Awarded New Patent for its Innovative Compounds That Selectively Target Peripheral Cannabinoid Receptors
... effects associated with traditional cannabinoid agents
can be significant. For example, cannabinoid antagonists targeting the CB1 receptor, such as agents
being developed to treat obesity, have been ... RIMAs may have efficacy advantages over current agents
for depression and are expected to have a good ...
Peregrine Pharmaceuticals Awarded New U.S. Patent Further Strengthening Its Anti-Phospholipid Patent Portfolio
... Compounds Linked to Anti-Viral agents
TUSTIN, Calif., March 31 ... leadership in the field of phospholipid-targeting agents
for the treatment of life-threatening diseases. ... of phosphatidylethanolamine (PE)-binding agents
attached to a wide variety of anti-viral agents. ...
Nereus Pharmaceuticals Initiates ADVANCE, a Randomized Phase 2 Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer
... with chemotherapeutics and anti-angiogenesis agents
due to the different targets and mechanisms of ... this year.
About Vascular Disrupting agents
Vascular disrupting agents
are a newer class ...
Quest PharmaTech Announces Results Showing its Photosensitizer, SL052, is an Effective Immuno-Stimulant when combined with Immunotherapy for the Removal of Solid Tumors
... (PDT) used in combination with immunotherapeutic agents
in solid tumor animal models. The study, ... potency and effectiveness of immunotherapeutic agents
when used in combination with SL052 PDT.
The ... properties of activation with harmless physical agents
(light and ultrasound), combined with its ability ...
ECBC's Environmental BioMonitoring Laboratory Focuses on the Future
... and detection of seven biological warfare agents
utilizing robotics and high-speed ...
Presumptive identification for biowarfare agents
using enzyme-linked immunosorbent assays, ...
Identification of bacterial agents
using cell culture coupled with traditional and ...
Lilly to Acquire ImClone Systems in $6.5 Billion Transaction
... offering both targeted
therapies and oncolytic agents
along with a pipeline spanning all phases ... a
complementary portfolio of leading oncolytic agents
and targeted therapies
including GEMZAR(R), ... a setting
with resuscitation equipment and other agents
necessary to treat
anaphylaxis (eg, epinephrine, ...
ReceptorBio Announces Diabetes License Agreement With Telik
... be co-administered
with other anti-diabetic agents
including insulin. The insulin ... novel class of insulin sensitizers."
"The oral agents
currently available on the market for the ... of action. ReceptorBio believes its novel agents
positioned to be first in their class, ...
Tests show LLNL detection instrument can monitor the air for all major terrorist threat substances
... the air for virtually all of the major threat agents
that could be used by terrorists.
This type of ... can autonomously detect multiple types of threat agents
and trigger alarms within less than a minute," ... our experiments with all these types of threat agents
within minutes of each other without ...
New Aptivus(R) (tipranavir) Oral Solution Approved for Treatment-Experienced Pediatric and Adolescent HIV Patients
... is not recommended.
-- The use of other active agents
with APTIVUS/r is associated with a
greater ... to the older
groups (37 percent and 31 percent). agents
approved by the FDA in the past
five months were ... the risk of
bleeding such as antiplatelet agents
and anticoagulants, or who are ...
NIST/NIH micromagnets show promise as colorful 'smart tags' for magnetic resonance imaging
... solutions now used as image-enhancing contrast agents
in MRI, the NIST/NIH micro-magnets rely on a ... injectable MRI contrast agents. MRI contrast agents
enhance images by altering the magnetic field ... hydrogen nuclei in water. Conventional contrast agents
are chemically synthesized whereas the new ...
ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
... and success in
bringing novel anti-cancer agents
to the market. This deal represents a
significant ... where the
therapeutic potential of anti-PlGF agents
to treat cancer was first
developed in the ... inhibitors such as TB-403 are therapeutic agents
by blocking the development of new ...
Dermatologists Report Increased Use of Biologics in the Treatment of Psoriasis
... Despite the increased use of biologics, topical agents
remain the most
commonly prescribed therapy for ... around its formulation. While the use of
to treat psoriasis increases with disease ... Dermatology setting although interest
in these agents
About BioTrends Research Group, Inc.
Sangart, Inc. Completes Enrollment in Second Phase III Study of Hemospan, a Novel Oxygen Transport Agent
... of therapeutic oxygen transport agents
that it has completed enrollment ... of
No similar oxygen transport agents
are currently on the market in
Europe or the ... designed for use as therapeutic oxygen transport agents
potential alternatives to blood ...
Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights
... second-generation technetium-based imaging agents
to aid in the diagnosis of PD, Dementia with ... primate studies that our technetium-based agents
are effective in binding the to DAT in sufficient ... radiolabeling procedure for our technetium agents
that results in a high purity, high yield product ...
Department of Defense Awards $5.8 Million Contract Modification Providing Additional Funding for PharmAthene's Protexia(R) Program
as a prophylactic against nerve agents
would add a valuable capability to
the spectrum ... has been shown to bind with nerve agents
lethality in in vivo challenge studies ... other classical chemical warfare agents
such as vesicants, choking
agents and blood ...
Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
... scientific meeting on anti-angiogenic agents
-- the 10th Annual International Symposium on Anti-Angiogenic agents
(Angio 2008) -- highlighting the positive ... of human breast cancer. Selective anti-VEGF agents
may have potential advantages over non-selective ...
FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy
... -- The use of other active antiretroviral agents
with INTELENCE is associated with an ... the 47th Interscience Conference on
and Chemotherapy (ICAAC) in September 2007.
... -- Coadministration of INTELENCE with other agents
such as substrates, inhibitors, or inducers ...
Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy
combination with the chemotherapy agents
paclitaxel and carboplatin as
first-line therapy ... increased by co-treatment with
including carboplatin and taxanes such ... that was
significantly greater than any of the agents
alone or the combination of
carboplatin and a ...
ICBS acquires 30% interest in Bacteria Bank Ltd.
... of potentially promising anti-microbial agents
developed by biotech companies or researchers in ... against a wide array of Gram negative agents
( E. coli, Salmonella, shigella, and other ... the world)
4. susceptibility testing of new agents
against Streptococcus pneumoniae ...
First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs
... tumors refractory to currently
marketed platinum agents
carboplatin, cisplatin and oxaliplatin. ... DNA cross links. About Platinum Anticancer agents
are the most broadly used cytotoxic drugs used in ...
Oncologists Want to See Significant Improvement in Overall Survival Before Adopting Targeted Polytherapy in a First-Line Setting
... of Managed Care Organizations Fail to Cover agents
Proven Benefit for Cancer Patients, ... Forum report
entitled Premium-Priced Targeted agents
in Oncology: Clinician and Payer
Attitudes to ... care
organizations (MCOs) fail to cover both agents
where two similar targeted
agents are available. ...
FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections
... DORIBAX belongs to a class of antibacterial agents
which are important for ... life-threatening Gram-negative infections. "New agents
are urgently needed to effectively treat ... reported with
use of nearly all antibacterial agents
and may range in severity from mild
diarrhea to ...
New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrine's Anti-PS Technology Platform
... agent. This new
research shows that these same agents
also have the potential to enhance
cancer ... The new class of immunocytokine fusion protein agents
is part of
Peregrine's Vascular Targeting Agent ... covering
broad concepts of tumor therapy using agents
that target tumor blood
vessels. This study, ...
EpiStem Successfully Complete First Year of Mucositis Tests for NIH Biodefence Programme
... problem following
high-dose radiation exposure. agents
that mitigate these effects could
reduce sickness ... performed by
EpiStem are also likely to identify agents
with oncology supportive care
applications - agents
that will reduce the severe ulceration and ...
Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
... we find new effective treatment options. agents
such as Cloretazine(R)
(VNP40101M) have the ... innovative cancer therapeutics. Vion has two agents
clinical trials. Cloretazine(R) (VNP40101M), a ... vector used to deliver anticancer agents
directly to tumors. For
additional information on ...
Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech
... blocks VEGF from binding to VEGF receptor 2 (VEGFR2), while non-selective agents
such as Avastin block binding to both VEGFR2 and VEGF receptor 1 (VEGFR1). Selective anti-VEGF agents
such as r84 may have safety and efficacy advantages over non-selective ...
Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine
... a European patent for a novel device and methods for linking biological agents
to labels for diagnostic and therapeutic applications. The technology, ... of radiolabeled anti-cancer antibodies, but is applicable to other agents
as well. A study published today in the July 2009 issue of The Journal ...
Pasteuria Bioscience Receives EPA Registration for Nematode Control
... in soil that have long been recognized as promising biological control agents
for plant-parasitic nematodes.
"We're very pleased to receive this ... have considered Pasteuria to be among the most promising biological agents
for control of plant-parasitic nematodes, but until recently, no one was ...
Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress
... administration, CPX-351 produced prolonged half-lives for both agents
and accumulation of the drugs over the three dose induction course ... allowing the release of the synergistic 5:1 molar ratio of the active agents
intracellularly, and demonstrated that CPX-351 is taken up in higher ...
Celsense, Inc Receives NIH Grant to Translate Cell Imaging Technology for Clinical Use
... novel pre-clinical and clinical-grade cellular and molecular imaging agents
used to non-invasively monitor biological processes in living systems. The core innovations of the Company involve proprietary imaging agents
that can be used to observe the trafficking of cells using magnetic ...
Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma
... study at ASCO.
"Anthracycline-related drugs can be effective salvage agents
in aggressive NHL, but our use of them is limited by the significant ... treated with pixantrone than among patients who received comparator agents
(8.8% vs. 4.5%). Events considered cardiac disorders included cardiac ...
Sinobiopharma Updates on Progress; Projects Increases in Sales and Revenues In 2009
... for Cisatracurium Besylate, Sinobiopharma's flagship drug, with business agents
who distribute the Company's products in 30 provinces and key major cities ... China, the Company's current therapeutic focus is on anesthesia-assisted agents
and cardiovascular drugs.